Understanding how gut bacteria affect cancer treatment responses
Deciphering the crosstalk between bacteria and their mammalian hosts
This study is looking at how the bacteria in our gut can affect cancer treatments by influencing our immune system, and it aims to find ways to make these treatments work better for people with cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado NIH-funded |
| Lab location | 1 site (Boulder, UNITED STATES) |
| Project ID | NIH-10473037 on NIH RePORTER |
What this research studies
This research investigates the interactions between gut bacteria and the human immune system, particularly how these bacteria can influence the effectiveness of cancer immunotherapy. By examining the molecular mechanisms involved, the study aims to uncover how bacteria produce small molecules that can activate or inhibit immune responses. The focus is on the cGAS-STING pathway, which plays a crucial role in the body's defense against cancer and infections. This research could lead to new insights into improving cancer treatments by considering the role of the microbiome.
Who could benefit from this research
Good fit: Ideal candidates for this research include cancer patients undergoing immunotherapy who are interested in understanding how their gut bacteria may affect treatment outcomes.
Not a fit: Patients without cancer or those not receiving immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could enhance the effectiveness of cancer immunotherapies by tailoring treatments based on individual microbiome profiles.
How similar studies have performed: Other research has shown promising results in understanding the microbiome's influence on cancer treatment, indicating that this approach has potential for significant breakthroughs.
Where this research is happening
Boulder, UNITED STATES
- University of Colorado — Boulder, United States (Active)
Researchers
- Principal investigator: Whiteley, Aaron Thomas — University of Colorado
- Study coordinator: Whiteley, Aaron Thomas
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.